CorMedix Inc. (CRMD) vs Monopar Therapeutics Inc. (MNPR)
A side-by-side comparison of CorMedix Inc. and Monopar Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRMD
CorMedix Inc.
$7.28HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
MNPR
Monopar Therapeutics Inc.
$79.57HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CRMD vs MNPR
growth of $100 · dividends reinvested · last 7yCRMD +12.6% (+1.7%/yr)MNPR -40.9% (-7.2%/yr)CRMD compounded faster over this window
CRMD MNPR
CRMD vs MNPR: by the numbers
- •CRMD is the larger company ($571M vs $533M market cap).
- •CRMD is profitable (40.49% net margin) while MNPR runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | CRMD | MNPR |
|---|---|---|
| P/E ratio | 3.42 | N/A |
| Forward P/E | 14.71 | N/A |
| P/S ratio | 1.24 | N/A |
| P/B ratio | 1.24 | 4.07 |
| EV / EBITDA | 1.82 | N/A |
| FCF yield | 43.82% | N/A |
Profitability
| Metric | CRMD | MNPR |
|---|---|---|
| Gross margin | 82.78% | 0.00% |
| Operating margin | 46.95% | 0.00% |
| Net margin | 40.49% | 0.00% |
| ROE | 40.62% | -13.64% |
| ROIC | 27.87% | -16.89% |
Growth (annualized)
| Metric | CRMD | MNPR |
|---|---|---|
| Revenue CAGR (5Y) | 352.03% | N/A |
| Total return CAGR (5Y) | 9.70% | 27.38% |
Frequently asked
- Is CRMD or MNPR more profitable?
- CRMD runs the higher net margin — CRMD at 40.49% versus MNPR at 0.00%.
- How have CRMD and MNPR total returns compared?
- Over the past 5 years, CRMD delivered 9.70% and MNPR delivered 27.38% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
CorMedix P/E ratioCorMedix ROEMonopar Therapeutics ROECorMedix operating marginMonopar Therapeutics operating marginCorMedix revenue growthMonopar Therapeutics revenue growthCorMedix free cash flowMonopar Therapeutics free cash flow
CorMedix & Monopar Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.